Open-Systems-Pharmacology · osp-reports-creator · Jul 14, 2026 · Jul 14, 2026
diff --git a/..._qualification-cyp1a2-ddi/DDIRatio_1_ddi_ratio_plot_AUC_predictedVsObserved.png b/..._qualification-cyp1a2-ddi/DDIRatio_1_ddi_ratio_plot_AUC_predictedVsObserved.png
diff --git a/..._qualification-cyp1a2-ddi/DDIRatio_1_ddi_ratio_plot_AUC_residualsVsObserved.png b/..._qualification-cyp1a2-ddi/DDIRatio_1_ddi_ratio_plot_AUC_residualsVsObserved.png
diff --git a/...qualification-cyp1a2-ddi/DDIRatio_1_ddi_ratio_plot_CMAX_predictedVsObserved.png b/...qualification-cyp1a2-ddi/DDIRatio_1_ddi_ratio_plot_CMAX_predictedVsObserved.png
diff --git a/...qualification-cyp1a2-ddi/DDIRatio_1_ddi_ratio_plot_CMAX_residualsVsObserved.png b/...qualification-cyp1a2-ddi/DDIRatio_1_ddi_ratio_plot_CMAX_residualsVsObserved.png
diff --git a/...atio_1_perpetrator_Ethinylestradiol_ddi_ratio_plot_CMAX_predictedVsObserved.png b/...atio_1_perpetrator_Ethinylestradiol_ddi_ratio_plot_CMAX_predictedVsObserved.png
diff --git a/...i/DDIRatio_1_perpetrator_Fluvoxamine_ddi_ratio_plot_AUC_predictedVsObserved.png b/...i/DDIRatio_1_perpetrator_Fluvoxamine_ddi_ratio_plot_AUC_predictedVsObserved.png
diff --git a/...i/DDIRatio_1_perpetrator_Fluvoxamine_ddi_ratio_plot_AUC_residualsVsObserved.png b/...i/DDIRatio_1_perpetrator_Fluvoxamine_ddi_ratio_plot_AUC_residualsVsObserved.png
diff --git a/.../DDIRatio_1_perpetrator_Fluvoxamine_ddi_ratio_plot_CMAX_predictedVsObserved.png b/.../DDIRatio_1_perpetrator_Fluvoxamine_ddi_ratio_plot_CMAX_predictedVsObserved.png
diff --git a/.../DDIRatio_1_perpetrator_Fluvoxamine_ddi_ratio_plot_CMAX_residualsVsObserved.png b/.../DDIRatio_1_perpetrator_Fluvoxamine_ddi_ratio_plot_CMAX_residualsVsObserved.png
diff --git a/...yp1a2-ddi/DDIRatio_1_victim_Caffeine_ddi_ratio_plot_AUC_predictedVsObserved.png b/...yp1a2-ddi/DDIRatio_1_victim_Caffeine_ddi_ratio_plot_AUC_predictedVsObserved.png
diff --git a/...yp1a2-ddi/DDIRatio_1_victim_Caffeine_ddi_ratio_plot_AUC_residualsVsObserved.png b/...yp1a2-ddi/DDIRatio_1_victim_Caffeine_ddi_ratio_plot_AUC_residualsVsObserved.png
diff --git a/...p1a2-ddi/DDIRatio_1_victim_Caffeine_ddi_ratio_plot_CMAX_predictedVsObserved.png b/...p1a2-ddi/DDIRatio_1_victim_Caffeine_ddi_ratio_plot_CMAX_predictedVsObserved.png
diff --git a/...p1a2-ddi/DDIRatio_1_victim_Caffeine_ddi_ratio_plot_CMAX_residualsVsObserved.png b/...p1a2-ddi/DDIRatio_1_victim_Caffeine_ddi_ratio_plot_CMAX_residualsVsObserved.png
diff --git a/...1a2-ddi/DDIRatio_1_victim_Tizanidine_ddi_ratio_plot_AUC_predictedVsObserved.png b/...1a2-ddi/DDIRatio_1_victim_Tizanidine_ddi_ratio_plot_AUC_predictedVsObserved.png
diff --git a/...1a2-ddi/DDIRatio_1_victim_Tizanidine_ddi_ratio_plot_AUC_residualsVsObserved.png b/...1a2-ddi/DDIRatio_1_victim_Tizanidine_ddi_ratio_plot_AUC_residualsVsObserved.png
diff --git a/...a2-ddi/DDIRatio_1_victim_Tizanidine_ddi_ratio_plot_CMAX_predictedVsObserved.png b/...a2-ddi/DDIRatio_1_victim_Tizanidine_ddi_ratio_plot_CMAX_predictedVsObserved.png
diff --git a/...a2-ddi/DDIRatio_1_victim_Tizanidine_ddi_ratio_plot_CMAX_residualsVsObserved.png b/...a2-ddi/DDIRatio_1_victim_Tizanidine_ddi_ratio_plot_CMAX_residualsVsObserved.png
diff --git a/...xamine-ddi/comparison_time_profile_Culm_Merdeck_2005__Caffeine_250_mg_po__3.png b/...xamine-ddi/comparison_time_profile_Culm_Merdeck_2005__Caffeine_250_mg_po__3.png
diff --git a/...luvoxamine-ddi/comparison_time_profile_Jeppesen_1996__Caffeine_200_mg_po__2.png b/...luvoxamine-ddi/comparison_time_profile_Jeppesen_1996__Caffeine_200_mg_po__2.png
diff --git a/...luvoxamine-ddi/comparison_time_profile_Granfors_2004__Tizanidine_4_mg_po__4.png b/...luvoxamine-ddi/comparison_time_profile_Granfors_2004__Tizanidine_4_mg_po__4.png
diff --git a/...e-mexiletine-ddi/comparison_time_profile_Joeres_1987__Caffeine_336_mg_po__6.png b/...e-mexiletine-ddi/comparison_time_profile_Joeres_1987__Caffeine_336_mg_po__6.png
diff --git a/DDI_Qualification_CYP1A2/report.md b/DDI_Qualification_CYP1A2/report.md
@@ -1,9 +1,9 @@
 # CYP1A2 DDI Qualification
 
-| Version                         | 2.0-OSP12.3                                                   |
+| Version                         | 2.0-OSP13.0                                                   |
 | ------------------------------- | ------------------------------------------------------------ |
 | Qualification Plan Release      | https://github.com/Open-Systems-Pharmacology/Qualification-DDI-CYP1A2/releases/tag/v2.0 |
-| OSP Version                     | 12.3                                                          |
+| OSP Version                     | 13.0                                                          |
 | Qualification Framework Version | 3.7                                                          |
 
 This qualification report is filed at:
@@ -338,11 +338,11 @@ In the plots,
 |DataID |Perpetrator                    |Victim         |Predicted AUC Ratio |Observed AUC Ratio |Pred/Obs AUC Ratio |Predicted CMAX Ratio |Observed CMAX Ratio |Pred/Obs CMAX Ratio |Reference        |
 |:------|:------------------------------|:--------------|:-------------------|:------------------|:------------------|:--------------------|:-------------------|:-------------------|:----------------|
 |6110   |Ethinylestradiol, 0.03 mg, PO, |Caffeine, PO   |5.84                |2.13               |2.74               |1.10                 |1.15                |0.96                |Balogh 1995      |
-|13017  |Fluvoxamine, 100 mg, PO,       |Tizanidine, PO |39.12               |33.00              |1.19               |16.00                |12.10               |1.32                |Granfors 2004    |
+|13017  |Fluvoxamine, 100 mg, PO,       |Tizanidine, PO |38.77               |33.00              |1.17               |15.95                |12.10               |1.32                |Granfors 2004    |
 |13018  |Mexiletine, 50 mg, PO,         |Tizanidine, PO |2.48                |3.42               |0.73               |2.42                 |3.22                |0.75                |Momo 2010        |
 |14002  |Ethinylestradiol, 20 mg, PO,   |Tizanidine, PO |4.41                |3.92               |1.13               |3.75                 |3.02                |1.24                |Granfors 2005    |
-|14004  |Fluvoxamine, 100 mg, PO,       |Caffeine, PO   |9.97                |7.16               |1.39               |1.08                 |1.09                |0.99                |Jeppesen 1996    |
-|14006  |Fluvoxamine, 100 mg, PO,       |Caffeine, PO   |13.64               |13.71              |0.99               |1.34                 |1.40                |0.96                |Culm-Merdek 2005 |
+|14004  |Fluvoxamine, 100 mg, PO,       |Caffeine, PO   |10.02               |7.16               |1.40               |1.08                 |1.09                |0.99                |Jeppesen 1996    |
+|14006  |Fluvoxamine, 100 mg, PO,       |Caffeine, PO   |13.65               |13.71              |1.00               |1.34                 |1.40                |0.96                |Culm-Merdek 2005 |
 |14008  |Mexiletine, 200 mg, PO,        |Caffeine, PO   |1.66                |2.83               |0.59               |1.00                 |1.89                |0.53                |Joeres 1987      |
 |14010  |Fluvoxamine, 50 mg, PO,        |Mexiletine, PO |1.31                |1.55               |0.84               |1.08                 |1.16                |0.93                |Kusumoto 2001    |
 
@@ -701,7 +701,7 @@ In the plots,
 
 |PK parameter |GMFE |
 |:------------|:----|
-|AUC          |1.19 |
+|AUC          |1.18 |
 |CMAX         |1.07 |
 
 <br>
@@ -777,7 +777,7 @@ In the plots,
 
 |PK parameter |GMFE |
 |:------------|:----|
-|AUC          |1.23 |
+|AUC          |1.22 |
 |CMAX         |1.30 |
 
 <br>

diff --git a/DDI_Qualification_CYP1A2/report.pdf b/DDI_Qualification_CYP1A2/report.pdf